Abstract: The present invention is a method for enhancing the efficacy of an active ingredient in a human comprising: administering to said human a product comprising: a kavalactone component and an active ingredient, wherein said active ingredient is selected from the group consisting of a therapeutic, a pharmaceutical, a nutraceutical and a botanical, and wherein said kavalactone component comprises a methysticin component, a dihydromethysticin component, a desmethoxyyangonin component, a yangonin component, a dihydrokavain component, and a kavain component, and wherein said kavalactone component is between about 0.1% to about 75%, by mass, of said product.

Abstract: A method of producing a processed kava product involves using an extraction solvent, such as liquid CO2, to preferentially extract different kavalactones from the source material at different rates. By controlling the extraction parameters and stopping the extraction before all of the kavalactones have been extracted or allowing the extracted kavalactones to be preferentially precipitated in one or more collection environments, a processed kava product can be produced that has a kavalactone distribution profile that can differ substantially from that of the source material. As a result, roots from a less desirable kava cultivar can be used to produce a processed kava product which has a kavalactone distribution profile that is similar to that of a highly desired cultivar. The kava paste can be further processed to produce a dry flowable powder suitable for use in, e.g., a tableting formula. A rapid dissolve tablet formulation for use in the delivery of kavalactones and other botanicals is also disclosed.

Abstract: A method of producing a processed kava product involves using an extraction solvent, such as liquid CO2, to preferentially extract different kavalactones from the source material at different rates. By controlling the extraction parameters and stopping the extraction before all of the kavalactones have been extracted or allowing the extracted kavalactones to be preferentially precipitated in one or more collection environments, a processed kava product can be produced that has a kavalactone distribution profile that can differ substantially from that of the source material. As a result, roots from a less desirable kava cultivar can be used to produce a processed kava product which has a kavalactone distribution profile that is similar to that of a highly desired cultivar. A material having a preferred kavalactone distribution profile is also disclosed. The kava paste can be further processed to produce a dry flowable powder suitable for use in, e.g., a tableting formula.

Abstract: A method of producing a processed kava product involves using an extraction solvent, such as liquid CO2, to preferentially extract different kavalactones from the source material at different rates. By controlling the extraction parameters and stopping the extraction before all of the kavalactones have been extracted or allowing the extracted kavalactones to be preferentially precipitated in one or more collection environments, a processed kava product can be produced that has a kavalactone distribution profile that can differ substantially from that of the source material. As a result, roots from a less desirable kava cultivar can be used to produce a processed kava product which has a kavalactone distribution profile that is similar to that of a highly desired cultivar. The kava paste can be further processed to produce a dry flowable powder suitable for use in, e.g., a tableting formula. A rapid dissolve tablet formulation for use in the delivery of kavalactones and other botanicals is also disclosed.

Abstract: A method of producing a processed kava product involves using an extraction solvent, such as liquid CO2, to preferentially extract different kavalactones from the source material at different rates. By controlling the extraction parameters and stopping the extraction before all of the kavalactones have been extracted or allowing the extracted kavalactones to be preferentially precipitated in one or more collection environments, a processed kava product can be produced that has a kavalactone distribution profile that can differ substantially from that of the source material. As a result, roots from a less desirable kava cultivar can be used to produce a processed kava product which has a kavalactone distribution profile that is similar to that of a highly desired cultivar. The kava paste can be further processed to produce a dry flowable powder suitable for use in, e.g., a tableting formula. A rapid dissolve tablet formulation for use in the delivery of kavalactones is also disclosed.

Abstract: The present invention is a method for enhancing the efficacy of an active ingredient in a human comprising: administering to said human a product comprising: a kavalactone component and an active ingredient, wherein said active ingredient is selected from the group consisting of a therapeutic, a pharmaceutical, a nutraceutical and a botanical, and wherein said kavalactone component comprises a methysticin component, a dihydromethysticin component, a desmethoxyyangonin component, a yangonin component, a dihydrokavain component, and a kavain component, and wherein said kavalactone component is between about 0.1% to about 75%, by mass, of said product.

Abstract: The present invention comprises methods for making compositions derived from Ilex species, particularly Ilex paraguariensis, having lowered caffeine and tannin concentrations, compositions made by such methods, oral delivery formulations, and methods of use of such compositions. In particular, the present invention comprises methods for making maté compositions that have a predetermined characeteristic, such as a lowered amount of caffeine, elevated amounts of caffeoyls, and/or lowered amounts of tannin compounds compared to the native maté plant materials. Further, the invention comprises methods of additional processing steps to produce compositions having a predetermined alkaloid ratio or profiles to meet particular considerations for final products. The compositions of the present invention may be processed for specific uses such as tablets or other oral delivery vehicles. These compositions may be used in methods for treatment of physiological and medical conditions.

Abstract: The present invention comprises methods and compositions comprising Areca extract compositions and compositions comprising extracts of Ilex paraguariensis or theobromine. Methods of the invention comprise methods of making pharmaceutical or nutriceutical products comprising Areca catechu extract compositions and mate' extract compositions or theobromine, and methods of use of the extracted products and pharmaceutical and nutriceutical products. The present invention also comprises methods for treating conditions related to mental and physical fatigue and obesity, as well as, enhancement of mental focus, cognition, and a sense of well being, comprising administering the compositions of the present invention.

Abstract: The present invention comprises methods for making compositions derived from Ilex species, particularly Ilex paraguariensis, having lowered caffeine and tannin concentrations, compositions made by such methods, oral delivery formulations, and methods of use of such compositions. In particular, the present invention comprises methods for making maté compositions that have a predetermined characeteristic, such as a lowered amount of caffeine, elevated amounts of caffeoyls, and/or lowered amounts of tannin compounds compared to the native maté plant materials. Further, the invention comprises methods of additional processing steps tp produce compositions having a predetermined alkaloid ratio or profiles to meet particular considerations for final products. The compositions of the present invention may be processed for specific uses such as tablets or other oral delivery vehicles. These compositions may be used in methods for treatment of physiological and medical conditions.

Abstract: The present invention comprises compositions comprising combinations of kava extract compositions in combination with one or more anxiolytics and methods for treating conditions related to the various anxiety disorders comprising administering the compositions of the present invention. The invention further provides methods for enhancing the therapeutic activity of an anxiolytic comprising administering the anxiolyitc in combination with extract of Piper methysticin.

Abstract: The present invention relates to methods and compositions comprising Areca catechu extracts and Piper betel extracts. Compositions comprise Areca catechu extracts that comprise alkaloid compounds in ratios that are different from the ratios found in native Areca plant material. Methods of the present invention comprise extractions of Areca catechu and Piper betel, making the compositions comprising Areca catechu and Piper betel and methods of providing compositions that mimic the effects in humans of chewing betel quid and have reduced carcinogenicity.

Abstract: The present invention comprises compositions comprising combinations of compositions of extracts of kava mate' extract compositions or theobromine. The invention further comprises methods for treating conditions related to mental and physical fatigue, anxiety, muscle tension, nervous depression, headache, obesity, and mild pain as well a enhancement of cognition and mental focus comprising administering effective amounts of the compositions of the present invention.

Abstract: This invention is related to an improved composition for treating heart conditions. More specifically, the present invention is related to an improved composition for treating heart conditions containing borneol, rosmarinic acid and a ginsenoside selected from the group consisting of ginsenoside Rg1 and ginsenoside Rb1.

Abstract: A latex composition for hair care containing a spray-dried hybrid-graft copolymer of a sulfopolyester and an acid-functional polymer segment. The acid-functional polymer segment is formed from at least one acid-functional monomer, at least one ethylenically unsaturated monomer, and at least one amide-containing monomer. Such compositions exhibit superior curl retention even at high humidity.

Abstract: A method of producing a processed kava product involves using an extraction solvent, such as liquid CO2, to preferentially extract different kavalactones from the source material at different rates. By controlling the extraction parameters and stopping the extraction before all of the kavalactones have been extracted or allowing the extracted kavalactones to be preferentially precipitated in one or more collection environments, a processed kava product can be produced that has a kavalactone distribution profile that can differ substantially from that of the source material. As a result, roots from a less desirable kava cultivar can be used to produce a processed kava product which has a kavalactone distribution profile that is similar to that of a highly desired cultivar. The kava paste can be further processed to produce a dry flowable powder suitable for use in, e.g., a tableting formula. A rapid dissolve tablet formulation for use in the delivery of kavalactones and other botanicals is also disclosed.

Abstract: The present invention is a method for enhancing the efficacy of an active ingredient in a human comprising: administering to said human a product comprising: a kavalactone component and an active ingredient, wherein said active ingredient is selected from the group consisting of a therapeutic, a pharmaceutical, a nutraceutical and a botanical, and wherein said kavalactone component comprises a methysticin component, a dihydromethysticin component, a desmethoxyyangonin component, a yangonin component, a dihydrokavain component, and a kavain component, and wherein said kavalactone component is between about 0.1% to about 75%, by mass, of said product.

Abstract: A method of producing a processed kava product involves using an extraction solvent, such as liquid CO2, to preferentially extract different kavalactones from the source material at different rates. By controlling the extraction parameters and stopping the extraction before all of the kavalactones have been extracted or allowing the extracted kavalactones to be preferentially precipitated in one or more collection environments, a processed kava product can be produced that has a kavalactone distribution profile that can differ substantially from that of the source material. As a result, roots from a less desirable kava cultivar can be used to produce a processed kava product which has a kavalactone distribution profile that is similar to that of a highly desired cultivar. A material having a preferred kavalactone distribution profile is also disclosed. The kava paste can be further processed to produce a dry flowable powder suitable for use in, e.g., a tableting formula.

Abstract: A latex composition for hair care containing a spray-dried hybrid-graft copolymer of a sulfopolyester and an acid-functional polymer segment. The acid-functional polymer segment is formed from at least one acid-functional monomer, at least one ethylenically unsaturated monomer, and at least one amide-containing monomer. Such compositions exhibit superior curl retention even at high humidity.

Abstract: An improved method of cultivating kava plants is disclosed in which a growth medium is formed form a mound formed over a leveled bed of porous rocks, such as volcanic cinders. The bed material is substantially free of organic matter. The mound material is comprised of gravel smaller than the bed material, such as volcanic gravel, and includes organic matter. The kava plants are grown in the mound material. The plants can be harvested by lifting the plant from the mound using a modified forklift assembly. Relatively high mounded rows of other material can alternatively be used. An improved method of producing kava seedlings is also disclosed in which the apical tips of kava plant stems are cut. After buds develop along the stems, the stems are harvested, sectioned, and used to generate a large number of seedlings. Harvesting of remaining rootstock from the parent plant is delayed after harvesting of the stems to promote an increase in kavalactone concentration.

Abstract: The specification discloses a latex composition containing an acetoacetoxy-functional polymer which is the emulsion polymerization product of: